Amicus Therapeutics Inc. (NASDAQ:FOLD) shares fell 6.9% on Thursday . The stock traded as low as $6.58 and last traded at $6.64, with a volume of 4,349,813 shares. The stock had previously closed at $7.13.

Several brokerages have recently weighed in on FOLD. Leerink Swann reiterated an “outperform” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, June 1st. Bank of America Corp. began coverage on shares of Amicus Therapeutics in a report on Wednesday, May 18th. They set a “buy” rating and a $10.00 price objective on the stock. Robert W. Baird began coverage on shares of Amicus Therapeutics in a report on Wednesday, April 13th. They set a “neutral” rating and a $9.00 price objective on the stock. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a report on Monday. Finally, Goldman Sachs Group Inc. began coverage on shares of Amicus Therapeutics in a report on Wednesday, March 30th. They set a “neutral” rating and a $10.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $12.19.

The firm’s market cap is $863.93 million. The company’s 50-day moving average is $5.92 and its 200-day moving average is $6.85.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.01. Equities research analysts expect that Amicus Therapeutics Inc. will post ($1.35) EPS for the current fiscal year.

In related news, General Counsel Ellen Rosenberg purchased 15,000 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The shares were purchased at an average price of $7.67 per share, with a total value of $115,050.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

A number of institutional investors recently modified their holdings of FOLD. Jennison Associates LLC boosted its position in shares of Amicus Therapeutics by 3.3% in the fourth quarter. Jennison Associates LLC now owns 4,123,955 shares of the biopharmaceutical company’s stock worth $40,002,000 after buying an additional 133,138 shares in the last quarter. California Public Employees Retirement System boosted its position in shares of Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock worth $3,163,000 after buying an additional 11,600 shares in the last quarter. TD Asset Management Inc. boosted its position in shares of Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock worth $1,733,000 after buying an additional 2,600 shares in the last quarter. Swiss National Bank boosted its position in shares of Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 5,100 shares in the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock worth $1,138,000 after buying an additional 15,789 shares in the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.